Latest news articles

Added 10 months ago Drug news

FDA accepts NDA for lemborexant to treat insomnia

Eisai Co., Ltd. and Imbrium Therapeutics L.P. a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma, L.P. announced that...

Added 1 year ago Drug news

FDA approves Vaxelis six-in-one vaccine.- Sanofi Pasteur + MSD.

The FDA has approved Vaxelis (diphtheria, tetanus, pertussis, poliovirus, haemophilus b and hepatitis B vaccine) for use in children from...

Added 5 years ago Drug news

DTaP5-IPV-Hib-HepB1 (Six in One) vaccine filed at FDA- Merck Inc. + Sanofi Pasteur

Merck and Sanofi Pasteur, the vaccines division of Sanofi have announced that the Biologics License Application (BLA) filed for the...

Search all news articles for Poliomyelitis and other CNS infection

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more


Post-polio syndrome

The aim was to revise the existing EFNS task force document, with regard to a common defi nition of PPS, and evaluation of the existing evidence for the effectiveness and safety of therapeutic interventions.

Added 8 years ago

Search all guidelines for Poliomyelitis and other CNS infection

Journal articles

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

Objective: To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can...

Added 3 years ago

Search all journal articles for Poliomyelitis and other CNS infection